2026 年至 2032 年季节性流感疫苗市场（按类型、疫苗类型、疫苗效力、年龄层、分销管道和地区划分）

2026-2032年季节性流感疫苗市场评估

随着全球报告的流感病例不断增加，预计流感疫苗需求也将增加，刺激市场扩张。预计未来几年，全球流感疫苗市场将迅速扩张。这得益于老年人口的增长、人们意识的提高、政府疫苗宣传活动以及流感爆发频率的增加。预计2024年季节性流感疫苗市值约为79.7亿美元，到2032年将达到165.9亿美元。

市场参与企业和政府之间加强合作，在偏远地区提供流感疫苗（如猪流感疫苗），预计将加速市场成长，这将有助于市场在 2026 年至 2032 年期间以 8.2% 的复合年增长率成长。

季节性流感疫苗市场定义/概述

流感疫苗，又称为流感疫苗接种，可预防影响呼吸系统的感染疾病，并引起头痛、疲倦、流鼻水、发烧、肌肉疼痛和鼻塞等症状。流感是感染疾病，感染者咳嗽或打喷嚏时会迅速传播，并可能导致轻度至重度疾病。

季节性流感是由流感病毒引起的一种反覆发作的呼吸道疾病，与其诊断、治疗和预防相关的经济活动被称为季节性流感市场。

在目前的市场环境下，世界卫生组织（WHO）、美国疾病管制与预防中心（CDC）等政府机构已研发出多种已获许可的季节性流感疫苗。此外，WHO也启动了全球流感规划（GISRS）等活动，以监测全球流感活动。

此外，流感疫苗市场的扩张得益于政府措施推动的常规疫苗接种计画的增加，以及已开发国家和新兴经济体都将流感疫苗接种纳入其中。全球流感疫苗市场研究对该行业进行了全面的分析。

季节性流感疫苗特异性感染预防的主要变数是什么？

据世界卫生组织称，世界人口的成长、季节性流感疫苗

已接种许可疫苗的族群併发症的风险增加，包括孕妇、6 至 59 个月大的儿童、老年人和医护人员。

预防流感最有效的方法是接种已使用超过60年的可靠疫苗。由于流感病毒不断进化和变化，建议每年接种疫苗以保护自己免受流感侵害。

人们对流感和疫苗接种计画的认识不断提高，疫苗接种覆盖率也随之提高，市场也随之提高。流感相关疾病负担的日益加重，加上严重疫情和大流行的可能性，正在刺激对季节性流感疫苗作为预防措施的需求。

疫苗技术的进步，例如细胞和重组方法，提高了这些疫苗的效率、安全性和有效性。世界卫生组织（WHO）和美国疾病管制与预防中心等国际组织提倡将季节性流感疫苗接种作为预防策略，以减少疾病传播并保护弱势群体。

全球疫苗接种倡议，包括中低收入国家的疫苗宣传活动，正在透过扩大全球流感疫苗的可及性来促进市场成长。医疗保健提供者和医疗机构的需求，加上年度疫苗接种建议，正在推动市场成长，因为越来越多的人在流感季节寻求疫苗接种服务。 COVID-19 疫情凸显了针对流感等呼吸道病毒的有效疫苗接种策略的重要性，促使各国政府、医疗机构和製药公司将流感疫苗的研发和分发列为优先事项。

大型医疗保健公司正在投入大量精力和资金，用于疫苗研发，将其作为尖端治疗方法。例如，2021年8月，Sequirus投资了一种名为「自扩增mRNA」的未来流感疫苗技术。

季节性流感疫苗有哪些副作用？

随着研发不断提高耐用性、有效性并解决副作用问题，对流感疫苗的需求持续增长，同时确保当地的可用性和可负担性对于实现市场潜力至关重要。

任何疫苗都存在副作用，会以各种方式影响身体，例如皮疹、发烧、疼痛、发冷等，这限制了市场的成长。农村缺乏相关教育和经验，导致儿童未能接种疫苗，增加了幼年感染病毒性流感的风险。大众对疫苗接种的认知和信任度受到负面宣传的影响，这可能会阻碍市场的成长。

接种季节性流感疫苗的好处大于风险。市场可以透过克服这一限制、巧妙地应对担忧并促进疫苗安全来确保流感疫苗的更广泛使用。疫苗有其局限性，因为流感病毒会降低疫苗对季节性流行病毒株的有效性。

根据美国国家医学图书馆报道，新冠疫苗与季节性流感疫苗相比，两种疫苗的严重率和死亡率都有限，季节性流感疫苗的转变速度比新冠疫苗更快。

目录

第一章 季节性流感疫苗的全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章季节性流感疫苗的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球季节性流感疫苗市场（按类型）

• 概述
• 灭活疫苗
• 活病毒疫苗

6. 全球季节性流感疫苗市场（依疫苗类型）

• 概述
• 四价疫苗
• 三价疫苗

7. 全球季节性流感疫苗市场（以效价）

• 概述
• 四价
• 三价

8. 全球季节性流感疫苗市场（依给药途径）

• 概述
• 注射
• 鼻喷剂

9. 全球季节性流感疫苗市场（依年龄层）

• 概述
• 孩子们
• 成人

第十章 全球季节性流感疫苗市场依通路划分

• 概述
• 医院和零售药局
• 政府和机构供应

第 11 章全球季节性流感疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第十二章全球季节性流感疫苗市场的竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十三章 公司简介

• Sanofi
• Merck & Co
• Novartis
• GlaxoSmithKline
• Changsheng Bio-Technology Co., Ltd.
• Abbott Laboratories
• Aleph Biomedical

第十四章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十五章 附录

• 相关调查

Seasonal Influenza Vaccine Market Valuation-2026-2032

The demand for influenza vaccines is expected to increase in response to the rising number of influenza cases reported globally, fueling the market's expansion. The market for influenza vaccines is anticipated to expand quickly on a global scale over the next years. This can be attributed to the growth in elderly population, awareness, and government vaccination campaigns, as well as a rise in frequency of the flu. The seasonal influenza vaccine market was valued at around USD 7.97 Billion in 2024 and projected to reach USD 16.59 Billion valued in 2032.

It is anticipated that an increase in collaborations between industry participants and governments to guarantee the availability of flu shots, like the swine flu vaccine, in isolated regions will quicken market growth. It enables the market to grow at a CAGR of 8.2% from 2026-2032.

Seasonal Influenza Vaccine Market: Definition/ Overview

Influenza Vaccine is also known as flu shots. This vaccines protect against infection. It affects the respiratory system and causes symptoms such as headaches, lethargy, runny nose, fever, muscular aches, and congestion. Infection that spreads quickly through an infected person's cough and sneezes and can cause mild to severe illness.

The economic activity related to the diagnosis, treatment, and prevention of seasonal influenza, a recurrent respiratory ailment brought on by influenza viruses, is referred to as the seasonal influenza market.

The disease in the current market environment, the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other governmental agencies prescribe a number of licensed seasonal influenza vaccines. Moreover, the WHO has started the Global Influenza Program and GISRS, which work along with other organizations to monitor influenza activity worldwide.

Furthermore, increase of the influenza vaccine market is attributed to the growth of routine vaccination programs with government initiatives and inclusion of influenza vaccinations in these programs in both developed and developing nations. The study on the global influenza vaccine market offers a comprehensive analysis of the industry.

What are the Key Variables Factors for Seasonal Influenza Vaccines to Protect Agent Influence Disease?

The increasing population globally according to WHO, sessional influenza vaccines are

elevated risk complications to the group of pregnant women, children at the age of 6-59 months, old peoples, are getting licensed vaccines available including healthcare workers.

Most effective way to protect agent influenza disease by using reliable immunizations that have been in use for more than 60 years. An annual vaccination is advised to guard against influenza as the virus is ever-evolving and changing to protect it eroding.

The increasing awareness and vaccination programs about influenza is leading to higher vaccination rates and market growth. The growing burden of influenza-related illness, coupled with the potential for severe outbreaks or pandemics, has fueled demand for seasonal influenza vaccines as a preventive measure.

Advancements in vaccine technology, such as cell-based and recombinant methods, have improved the efficiency, safety, and effectiveness of these vaccines. International organizations like the World Health Organization and Centers for Disease Control and Prevention advocate for seasonal influenza vaccination as a preventive strategy to reduce disease transmission and protect vulnerable populations.

Global immunization initiatives, including vaccination campaigns in low- and middle-income countries, contribute to market growth by expanding access to influenza vaccines worldwide. Demand from healthcare providers and institutions, coupled with recommendations for annual vaccination, drives market growth as more individuals seek vaccination services during the influenza season. The COVID-19 pandemic has highlighted the importance of effective vaccination strategies against respiratory viruses like influenza, with governments, healthcare agencies, and pharmaceutical companies prioritizing research, development, and distribution of influenza vaccines.

Major healthcare companies are investing a great deal of effort and money into developing vaccines as cutting-edge treatments. As an illustration, in August 2021, Seqirus invested in the future influenza vaccine technology of self-amplifying mRNA.

What are the Side Effects of the Seasonal Influenza Vaccines?

The demand for influenza vaccines ongoing in research and development to enhance durability, efficacy, and address adverse effect issues. In additionally realizing the market potential is essential to provide accessibility and affordability across every region.

Any vaccines contain a number of side effects that can affect the body in many ways, including rashes, fever, pain, soreness, chills, and many more that limit the market's ability to grow. In rural areas there is a shortage of education and experience. Due to that children's are not vaccinated increasing the risk of contracting the viral flu from an early age. Public awareness or the trust about the vaccination can hinder the market growth because of negative publicity surrounding.

The advantages of getting vaccinated against seasonal influenza outweigh the dangers. The market may overcome this constraint and guarantee broader influenza vaccine use by skillfully resolving concerns and promoting vaccine safety. The virus reduce the vaccine effectiveness to the prevalent strain predicated for every season, which makes limitation of vaccines.

According to the National Library of Medicine, comparing the COVID-19 vaccine and seasonal influenza vaccine they may contain limited fraction of critical cases or morality rate. The seasonal influenza vaccine can transfer faster than the COVID-19.

Category-Wise Acumens

What Kind of Effectiveness Offered by Inactive Product to Contribute to Leading Position in Seasonal Influenza Vaccines Market?

As industry estimates the inactivated category will control the majority of the market in 2023. Industrialists' increasing focus on vaccines is driving a demand for inactivated vaccines in both developed and developing nations, as they are standardized based on specific virus strains. The greatest CAGR of the category over the projection period is primarily owing to the rising demand and high influenza prevalence.

There are ample evidence of their efficacy. Inactive Influenza Vaccines (IIVs) have a lengthy history building market demand, developing confidence, and offering significant protection against seasonal influenza viruses. When the circulating strains of the virus match the vaccination, they induce developed protection by targeting specific influenza antigens.

The safety profile of IIVs is very good. They are suitable for a wide spectrum of people and have moderate, transient negative effects.

Live attenuated category is expected to expand more slowly because of the many obstacles that companies must overcome to develop and approve vaccines. Furthermore, certain patients such as those with weak immune systems, asthma, and pregnant women should not receive the live attenuated vaccination.

How the Adoption of Seasonal Influenza Vaccines is Increasing in the Adults?

The majority of the market for seasonal influenza vaccinations is occupied by adults. Individuals with pre-existing medical disorders are more susceptible to serious influenza-related consequences, such as hospitalization and maybe fatality. The need for adult vaccinations is fueled by the necessity of vaccination for their protection. This is further supported by public health recommendations, which strongly advise high-risk persons to have an annual influenza vaccination.

The adult age group held a major share of the worldwide influenza vaccine market in terms of market share in 2022. There are significantly more adults than children in the population. The World Population Review of 2020 estimates that there were around 46 Billion adults over the age of 18, and approximately 1.2 Billion children between the ages of 12 and 18.

Furthermore, fewer influenza vaccinations are available for children than for adults. For example, the first COVID-19 vaccine approved in the United States was the Pfizer-BioNTech vaccine, and it was only approved for use in adults 16 years of age and older. As a result, adults are more likely than younger people to receive vaccinations.

Country/Region-wise Acumens

Does North America Hold Highest Market Share in the Seasonal Influenza Vaccines Market?

During, the projected period North America is anticipated to hold the highest market share. This has been brought to increased public awareness of influenza infections and the treatments that are available, government education initiatives and the development of new vaccines made possible by technological developments.

The existence of significant market players in the area and their substantial R&D spending are further factors contributing to the industry's growth. The influenza pandemic has become more often in North America, boosting the growth of seasonal influenza vaccine market.

The biggest markets for seasonal influenza vaccinations is North America. The high rate of flu in the area and the well-established healthcare system are the main drivers of the market. Children's at the age of six months and older should get the flu shot every year, according to the Centers for Disease Control and Prevention (CDC). The influenza vaccine market in North America is also being driven by a rise in awareness of the value of vaccination.

How will Seasonal Influenza Vaccine Market Fare in Asia Pacific?

The Asia Pacific area is turning into the global influenza vaccine market with the fastest rate of growth. Some of the main reasons propelling market expansion are governments' increased attention on immunization programs, growing per capita healthcare expenditures, and expanding healthcare infrastructure.

Whereas China, India, and Japan are leading the way in public health awareness campaigns because of their sizable populations and public health organizations' activities. Asia has experienced in sales of vaccines as a result of changing lifestyles and an increase in influenza-related diseases in recent years.

It is expected that Asia Pacific would have a higher CAGR over the projection period. The region's market is expected to develop as a result of the growing number of government activities to distribute these vaccines and raise awareness about influenza.

Competitive Landscape

The competitive landscape of the seasonal influenza vaccine market is characterized by several key players and factors that influence market dynamics, innovation, and strategic initiatives. These players completely based on Product portfolio, business segment, business strategies and recent development.

Some of the prominent players operating in the seasonal influenza vaccine market include:

• Sanofi
• Merck & Co
• Novartis
• GlaxoSmithKline
• Changsheng
• Bio-Technology Co., Ltd.
• OSIVAX
• Abbott Laboratories
• Aleph Biomedical.
• AstraZeneca
• SINOVAC
• Vietris Inc.
• BIKEN Co., Ltd
• GSK plc
• Pfizer Inc.
• Vaxess Technologies Inc.
• EMERGEX VACCINES

Latest Developments

• In October 2023, the outcomes of Moderna Inc.'s m-RNA-based vaccination for COVID-19 and influenza were revealed.
• In May 2023, GSK and CureVac launched the phase Ill influenza study for GSK's mRNA-based vaccination.
• In September 2022, Pfizer Inc. declared that the company's quadrivalent modified RNA influenza vaccine candidate has reached the first dose of participants in a pivotal phase 3 clinical study to assess the vaccine's immunogenicity, safety, tolerability, and efficacy.
• In February 2021, Pfizer and BioNTech declared that the COVID-19 vaccine was approved for use in emergency situations in the United States. This approval represented a significant turning point in the global fight against COVID-19 and showed that pharmaceutical companies can quickly create and commercialize vaccines to prevent the spread of infectious illnesses.

Seasonal Influenza Vaccines Market, By Category

• Type:
• Inactivated
• Live Attenuated
• Vaccine Type:
• Quadrivalent
• Trivalent
• Valency:
• Quadrivalent
• Trivalent
• Route of Administration:
• Injection
• Nasal Spray
• Age Group:
• Pediatric
• Adults
• Distribution Channel:
• Hospital & Retail Pharmacies
• Government & Institutional Supply
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL SEASONAL INFLUENZA VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL SEASONAL INFLUENZA VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Inactivated
• 5.3 Live Attenuated

6 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY VACCINE TYPE

• 6.1 Overview
• 6.2 Quadrivalent
• 6.3 Trivalent

7 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY VALENCY

• 7.1 Overview
• 7.1 Quadrivalent
• 7.1 Trivalent

8 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 Overview
• 8.1 Injection
• 8.1 Nasal Spray

9 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY AGE GROUP

• 9.1 Overview
• 9.1 Pediatric
• 9.1 Adults

10 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY DISTRIBUTION CHANNEL

• 10.1 Overview
• 10.1 Hospital & Retail Pharmacies
• 10.1 Government & Institutional Supply

11 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY

• 11.1 Overview
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 U.K.
  • 11.3.3 France
  • 11.3.4 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Rest of Asia Pacific
• 11.5 Rest of the World
  • 11.5.1 Latin America
  • 11.5.2 Middle East and Africa

12 GLOBAL SEASONAL INFLUENZA VACCINE MARKET COMPETITIVE LANDSCAPE

• 12.1 Overview
• 12.2 Company Market Ranking
• 12.3 Key Development Strategies

13 COMPANY PROFILES

• 13.1 Sanofi
  • 13.1.1 Overview
  • 13.1.2 Financial Performance
  • 13.1.3 Product Outlook
  • 13.1.4 Key Developments
• 13.2 Merck & Co
  • 13.2.1 Overview
  • 13.2.2 Financial Performance
  • 13.2.3 Product Outlook
  • 13.2.4 Key Developments
• 13.3 Novartis
  • 13.3.1 Overview
  • 13.3.2 Financial Performance
  • 13.3.3 Product Outlook
  • 13.3.4 Key Developments
• 13.4 GlaxoSmithKline
  • 13.4.1 Overview
  • 13.4.2 Financial Performance
  • 13.4.3 Product Outlook
  • 13.4.4 Key Developments
• 13.5 Changsheng Bio-Technology Co., Ltd.
  • 13.5.1 Overview
  • 13.5.2 Financial Performance
  • 13.5.3 Product Outlook
  • 13.5.4 Key Developments
• 13.6 Abbott Laboratories
  • 13.6.1 Overview
  • 13.6.2 Financial Performance
  • 13.6.3 Product Outlook
  • 13.6.4 Key Developments
• 13.7 Aleph Biomedical
  • 13.7.1 Overview
  • 13.7.2 Financial Performance
  • 13.7.3 Product Outlook
  • 13.7.4 Key Developments

14 KEY DEVELOPMENTS

• 14.1 Product Launches/Developments
• 14.2 Mergers and Acquisitions
• 14.3 Business Expansions
• 14.4 Partnerships and Collaborations

15 Appendix

• 15.1 Related Research